Compass Therapeutics' lead candidate, tovecimig, shows mixed data in various trials, with a significant upcoming phase 3 ...
Guggenheim initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price target Discover the Best Stocks and Maximize Your ...
Shares of Compass Therapeutics CMPX have skyrocketed 108.3% in a month after the company announced updates regarding its pipeline development programs and current cash position. The phenomenal ...
Shares of Compass Therapeutics (NASDAQ:CMPX) were up 8% in afternoon trading Monday after Guggenheim initiated coverage of ...
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused ...
The principle of momentum investing—though contrary to the traditional wisdom of buying low and selling high—suggests that investors can profit by buying rising stocks and selling them before ...
Shares of Compass Therapeutics stock opened at $3.38 on Wednesday. The firm has a market cap of $465.05 million, a P/E ratio of -9.13 and a beta of 1.17. Compass Therapeutics has a 12 month low of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback